Embecta Corp.

Listed Company

EMBCCIK 0001872789NasdaqLarge AcceleratedSurgical & Medical Instruments & ApparatusDelawareFY ends Sep 30

Period

FY 2025

Revenue

$1.08B

Net Income

$95.40M

Total Assets

$1.09B

Equity

$-650.60M

Shares Out

59.22M

Op. Cash Flow

$191.70M

Business

Embecta Corp. is a global medical device company providing solutions to improve the health and well‑being of people living with diabetes. It sells sterile, single‑use pen needles, safety pen needles, insulin syringes, safety insulin syringes and related injection safety devices. Its operations center on its core injection product business with integrated research and development, manufacturing, quality/regulatory and commercial functions. It manufactures in Ireland, the United States and China and distributes products to end users and healthcare providers in over 100 countries via retail, hospitals, pharmacies and institutional channels.

Summary from filing dated 2025-11-25

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-09-30	FY 2024 2024-09-30	FY 2023 2023-09-30	FY 2022 2022-09-30	FY 2021 2021-09-30
Revenues	1,080	1,123	1,121	1,130	1,165
Cost of products sold	404	388	371	355	365
Gross Profit	677	735	750	775	800
Selling and administrative expense	332	365	341	295	240
Research and development expense	37	79	85	67	63
Impairment expense	0	0	3	59	0
Other operating expenses	65	125	99	45	5
Total Operating Expenses	435	568	528	465	308
Operating Income	242	167	222	310	492
Interest expense, net	−107	−112	−107	−46	0
Other income (expense), net	2	−10	−9	−7	3
Income Before Income Taxes	136	44	106	257	495
Income tax provision (benefit)	41	−34	35	33	80
Net Income	95	78	70	224	415
Basic (in dollars per share)	1.64	1.36	1.23	3.92	7.28
Diluted (in dollars per share)	1.62	1.34	1.22	3.89	7.28

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-09-30	FY 2024 2024-09-30	FY 2023 2023-09-30	FY 2022 2022-09-30	FY 2021 2021-09-30
Cash and equivalents	226	268	326	331	0
Restricted cash	3	7	200,000	—	—
Trade receivables, net (net of allowance for doubtful accounts of $1.8 million and $2.8 million as of September 30, 2025 and September 30, 2024, respectively)	146	193	17	22	151
Materials	50	40	32	23	13
Work in process	12	5	8	6	21
Finished products	117	126	112	94	84
Total Inventories	179	172	152	123	118
Amounts due from Becton, Dickinson and Company	3	54	142	111	0
Prepaid expenses and other	75	69	111	78	23
Total Current Assets	631	761	749	665	292
Property, Plant and Equipment, Net	257	290	300	302	451
Goodwill and Intangible Assets	22	24	25	25	34
Deferred Income Taxes and Other Assets	180	210	140	96	11
Total Assets	1,091	1,285	1,214	1,086	788
Accounts payable	74	91	54	41	54
Accrued expenses	99	134	118	104	82
Amounts due to Becton, Dickinson and Company	16	43	73	67	0
Salaries, wages and related items	49	67	62	49	28
Current debt obligations	10	10	10	10	0
Current finance lease liabilities	3	3	4	4	0
Income taxes	10	27	34	27	0
Total Current Liabilities	262	374	354	301	164
Deferred Income Taxes and Other Liabilities	63	54	57	46	30
Long-Term Debt	1,389	1,565	1,594	1,598	0
Non Current Finance Lease Liabilities	29	30	32	33	0
Contingencies (Note 6)	—	—	—	—	—
Common stock, $0.01 par value Authorized - 250,000,000 Issued and outstanding - 58,496,113 as of September 30, 2025 and 57,707,285 as of September 30, 2024	600,000	600,000	600,000	600,000	—
Additional paid-in capital	80	53	28	10	—
Accumulated deficit	−446	−499	−541	−577	—
Accumulated other comprehensive loss	−286	−293	−309	−325	−271
Total Equity	−651	−738	−822	−891	594
Total Liabilities and Equity	1,091	1,285	1,214	1,086	788

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-09-30	FY 2024 2024-09-30	FY 2023 2023-09-30	FY 2022 2022-09-30	FY 2021 2021-09-30
Depreciation and amortization	41	36	33	32	38
Amortization of debt issuance costs	9	7	6	3	0
Amortization of cloud computing costs	10	6	0	0	—
Impairment of property, plant and equipment	11	0	3	59	14
Stock-based compensation	32	26	22	19	13
Deferred income taxes	18	−71	14	−27	−3
Trade receivables, net	44	−175	7	123	−32
Inventories	−6	−17	−29	−23	−18
Due from/due to Becton, Dickinson and Company	25	59	−23	−47	0
Prepaid expenses and other	9	40	−14	−44	−12
Accounts payable, accrued expenses and other current liabilities	−69	60	8	77	40
Income and other net taxes payable	−28	13	−13	10	0
Other assets and liabilities, net	1	−28	−16	7	500,000
Net Cash Provided by Operating Activities	192	36	68	412	456
Capital expenditures	−9	−16	−27	−24	−37
Net Cash Used for Investing Activities	−9	−16	−27	−24	−39
Payments on long-term debt	−185	−35	−10	−5	0
Payments related to tax withholding for stock-based compensation	−6	−3	−4	0	0
Payments on finance lease	−1	−1	−1	−2	0
Dividend payments	−35	−35	−34	−9	0
Net Cash Used for Financing Activities	−227	−73	−49	−48	−417
Effect of exchange rate changes on cash and equivalents and restricted cash	−1	1	3	−9	0
Net Change in Cash and equivalents and restricted cash	−46	−52	−4	331	0

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro